JP2014240408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014240408A5 JP2014240408A5 JP2014158170A JP2014158170A JP2014240408A5 JP 2014240408 A5 JP2014240408 A5 JP 2014240408A5 JP 2014158170 A JP2014158170 A JP 2014158170A JP 2014158170 A JP2014158170 A JP 2014158170A JP 2014240408 A5 JP2014240408 A5 JP 2014240408A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- eosinophilic
- prednisone
- treatment
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims description 14
- 108090001123 antibodies Proteins 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 9
- 206010065563 Eosinophilic bronchitis Diseases 0.000 claims description 8
- 210000003979 Eosinophils Anatomy 0.000 claims description 5
- 150000003431 steroids Chemical class 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 10
- 229960004618 prednisone Drugs 0.000 claims 10
- 102000000743 Interleukin-5 Human genes 0.000 claims 7
- 108010002616 Interleukin-5 Proteins 0.000 claims 7
- 230000003472 neutralizing Effects 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 208000006673 Asthma Diseases 0.000 claims 2
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims 2
- 208000006551 Parasitic Disease Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 208000006778 Allergic Bronchopulmonary Aspergillosis Diseases 0.000 claims 1
- 206010048594 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 206010002425 Angioedemas Diseases 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 206010009839 Coeliac disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014665 Endocarditis Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 206010057271 Eosinophilic colitis Diseases 0.000 claims 1
- 208000009812 Eosinophilic enteropathy Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 1
- 208000001797 Obstructive Sleep Apnea Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 241000243981 Onchocerca Species 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 210000003802 Sputum Anatomy 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 230000001419 dependent Effects 0.000 claims 1
- 201000004624 dermatitis Diseases 0.000 claims 1
- 231100000406 dermatitis Toxicity 0.000 claims 1
- 230000002327 eosinophilic Effects 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 201000001561 eosinophilic gastritis Diseases 0.000 claims 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 201000001181 parasitic helminthiasis infectious disease Diseases 0.000 claims 1
Description
もう1つの態様では、好酸球性気管支炎のヒトを処置するための方法が提供され、そこでは前記少なくとも1種類の抗IL−5抗体を含んでなる組成物は、第1の抗IL−5抗体および第2の抗IL−5抗体を含んでなる。少なくとも1種類の抗IL−5抗体を含んでなる組成物は、ステロイドと併用投与可能である。
本発明ではまた、好酸球性気管支炎を患うヒトにおいて、好酸球を減少させるための方法も提供され、その方法は、第1の抗IL−5抗体および第2の抗IL−5抗体を含んでなる組成物を投与することを含んでなる。本明細書では、少なくとも1種類の抗IL−5抗体がステロイドとともに併用投与される方法も提供される。
Claims (16)
- 少なくとも1種の中和型ヒト化抗ヒトIL−5抗体を含んでなる、ステロイドと併用投与して喘息を患う被験体における好酸球性気管支炎の処置に用いるための医薬組成物であって、ステロイドが、プレドニゾンであり、プレドニゾンが処置後少なくとも約90%減量され、被験体が、プレドニゾンによる処置にもかかわらず持続する好酸球性気管支炎を患う、医薬組成物。
- プレドニゾンの開始用量が5.0〜7.5mgであり、プレドニゾンの開始用量が処置後少なくとも約90%減量される、請求項1に記載の医薬組成物。
- 前記少なくとも1種の中和型ヒト化抗ヒトIL−5抗体が、配列番号19を含んでなる重鎖を含んでなる、請求項1に記載の医薬組成物。
- 前記少なくとも1種の中和型ヒト化抗ヒトIL−5抗体が、配列番号21を含んでなる軽鎖を含んでなる、請求項1に記載の医薬組成物。
- 前記少なくとも1種の中和型ヒト化抗ヒトIL−5抗体が、配列番号19を含んでなる重鎖と配列番号21を含んでなる軽鎖とを含んでなる、請求項1に記載の医薬組成物。
- 好酸球性気管支炎を患う被験体が、アトピー性皮膚炎、アレルギー性鼻炎、非アレルギー性鼻炎、慢性好酸球性肺炎、アレルギー性気管支肺アスペルギルス症、セリアック病、チャーグ・シュトラウス症候群、好酸球性筋肉痛症候群、過好酸球性症候群、偶発性血管性浮腫を含む浮腫反応、蠕虫感染症、寄生虫感染および/または寄生虫感染の処置に関連する好酸球増加症、オンコセルカ皮膚炎、好酸球性食道炎、好酸球性胃炎、好酸球性胃腸炎、好酸球性腸炎、好酸球性大腸炎、鼻マイクロポリープ症、鼻ポリープ症、閉塞性睡眠時無呼吸、クローン病、硬皮症および心内膜心筋線維症からなる群から選択される過剰な好酸球産生に関連する少なくとも1つの付加的障害を患っている、請求項1に記載の医薬組成物。
- 静脈内に投与するための、請求項1に記載の医薬組成物。
- 750mgの用量で投与するための、請求項7に記載の医薬組成物。
- 前記静脈用量を、30分以上かけて静脈内に投与するための、請求項7に記載の医薬組成物。
- 少なくとも1回用量を受容した後、ステロイド依存性好酸球性気管支炎の増悪を統計学的に有意に軽減するための、請求項1に記載の医薬組成物。
- 少なくとも1回投与した後に好酸球レベルを正常範囲内まで減少させるための、請求項1に記載の医薬組成物。
- 最終投与後前記好酸球レベルを少なくとも8週間、正常範囲内にとどめるための、請求項11に記載の医薬組成物。
- 第1の中和型ヒト化抗ヒトIL−5抗体および第2の中和型ヒト化抗ヒトIL−5抗体を含んでなる、請求項1に記載の医薬組成物。
- 前記好酸球レベルを、血液および/または痰において減少させるための、請求項11に記載の医薬組成物。
- 少なくとも1種の中和型ヒト化抗ヒトIL−5抗体とプレドニゾンを含んでなる、喘息を患う被験体における好酸球性気管支炎の処置に用いるための組合せ医薬であって、プレドニゾンが処置後少なくとも約90%減量され、被験体が、プレドニゾンによる処置にもかかわらず持続する好酸球性気管支炎を患う、組合せ医薬。
- プレドニゾンの開始用量が5.0〜7.5mgであり、プレドニゾンの開始用量が処置後少なくとも約90%減量される、請求項15に記載の組合せ医薬。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4036308P | 2008-03-28 | 2008-03-28 | |
US61/040,363 | 2008-03-28 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011502090A Division JP5917143B2 (ja) | 2008-03-28 | 2009-03-27 | 処置方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016214438A Division JP6457463B2 (ja) | 2008-03-28 | 2016-11-01 | 処置方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014240408A JP2014240408A (ja) | 2014-12-25 |
JP2014240408A5 true JP2014240408A5 (ja) | 2016-02-18 |
JP6069267B2 JP6069267B2 (ja) | 2017-02-01 |
Family
ID=41114741
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011502090A Active JP5917143B2 (ja) | 2008-03-28 | 2009-03-27 | 処置方法 |
JP2014158170A Active JP6069267B2 (ja) | 2008-03-28 | 2014-08-01 | 処置方法 |
JP2016214438A Active JP6457463B2 (ja) | 2008-03-28 | 2016-11-01 | 処置方法 |
JP2018238018A Pending JP2019065029A (ja) | 2008-03-28 | 2018-12-20 | 処置方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011502090A Active JP5917143B2 (ja) | 2008-03-28 | 2009-03-27 | 処置方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016214438A Active JP6457463B2 (ja) | 2008-03-28 | 2016-11-01 | 処置方法 |
JP2018238018A Pending JP2019065029A (ja) | 2008-03-28 | 2018-12-20 | 処置方法 |
Country Status (14)
Country | Link |
---|---|
US (3) | US9834600B2 (ja) |
EP (1) | EP2274009B1 (ja) |
JP (4) | JP5917143B2 (ja) |
KR (1) | KR20100134702A (ja) |
CN (1) | CN102026660A (ja) |
AU (1) | AU2009228163B2 (ja) |
BR (1) | BRPI0910854A2 (ja) |
CA (1) | CA2719786A1 (ja) |
EA (1) | EA201071137A1 (ja) |
ES (1) | ES2441945T3 (ja) |
IL (1) | IL208354A0 (ja) |
MX (1) | MX2010010667A (ja) |
WO (1) | WO2009120927A2 (ja) |
ZA (1) | ZA201006648B (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008113056A2 (en) | 2007-03-14 | 2008-09-18 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
BRPI0910854A2 (pt) * | 2008-03-28 | 2015-10-06 | Glaxosmithkline Llc | métodos de tratamento |
US20110190356A1 (en) | 2008-08-19 | 2011-08-04 | Knopp Neurosciences Inc. | Compositions and Methods of Using (R)- Pramipexole |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CA3162352A1 (en) | 2010-10-01 | 2012-04-05 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
AU2013243946A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
LT2922554T (lt) | 2012-11-26 | 2022-06-27 | Modernatx, Inc. | Terminaliai modifikuota rnr |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
CN105764507B (zh) | 2013-07-12 | 2019-07-19 | 诺普生物科学有限责任公司 | 治疗升高的嗜酸性粒细胞和/或嗜碱性粒细胞的水平 |
ES2871556T3 (es) | 2013-08-13 | 2021-10-29 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de la urticaria crónica |
ES2813674T3 (es) | 2013-08-13 | 2021-03-24 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
EA034864B1 (ru) * | 2014-09-08 | 2020-03-31 | Сефалон, Инк. | Способ лечения эозинофильной астмы со степенью тяжести от умеренной до тяжёлой |
MA42692A (fr) | 2015-08-24 | 2018-07-04 | Glaxosmithkline Ip No 2 Ltd | Compositions biopharmaceutiques |
TWI799417B (zh) | 2017-05-26 | 2023-04-21 | 英商葛蘭素史克智慧財產發展有限公司 | 生物製藥組成物及相關方法 |
KR20230067604A (ko) * | 2020-08-05 | 2023-05-16 | 아레테이아 테라퓨틱스, 인코포레이티드 | 중등도 내지 중증 천식의 치료를 위한 덱스프라미펙솔의 용도 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8800397D0 (en) | 1988-01-08 | 1988-02-10 | Sandoz Ltd | Improvements in/relating to organic compounds |
US5096704A (en) | 1988-11-03 | 1992-03-17 | Schering Corporation | Method of treating eosinophilia |
EP0441891A1 (en) | 1988-11-03 | 1991-08-21 | Schering Corporation | Method of preventing or reducing eosinophilia |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0533006A1 (en) | 1991-09-18 | 1993-03-24 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Chimaeric interleukin 5-receptor/immunoglobulin polypeptides |
AU676150B2 (en) | 1992-01-23 | 1997-03-06 | Merck Patent Gmbh | Monomeric and dimeric antibody-fragment fusion proteins |
ZA93779B (en) | 1992-02-06 | 1993-08-05 | Schering Corp | Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5. |
JPH06141885A (ja) | 1992-11-05 | 1994-05-24 | Chemo Sero Therapeut Res Inst | モノクローナル抗体 |
AU1289795A (en) | 1993-11-19 | 1995-06-06 | Baylor College Of Medicine | Monoclonal antibodies specific for human interleukin-5 |
GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
PL194312B1 (pl) * | 1994-12-23 | 2007-05-31 | Smithkline Beecham Corp | Przeciwciało monoklonalne neutralizujące gryzoni,linia hybrydoma, humanizowane przeciwciało, region CDR ciężkiego łańcucha immunoglobuliny, region CDR lekkiego łańcucha immunoglobuliny, cząsteczki kwasu nukleinowego, przeciwciało chimeryczne, kompozycja farmaceutyczna, izolowana sekwencja kwasu nukleinowego, rekombinowany plazmid i komórka gospodarza oraz sposób wytwarzania humanizowanego przeciwciała i sposób wspomagania diagnostyki alergii |
US5683892A (en) * | 1994-12-23 | 1997-11-04 | Smithkline Beecham Corporation | DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
US7399837B2 (en) | 1995-12-22 | 2008-07-15 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
US5783184A (en) | 1994-12-23 | 1998-07-21 | Smithkline Beecham Corporation | Method for treatment and diagnosis of IL-5 mediated disorders |
US6248723B1 (en) | 1997-06-10 | 2001-06-19 | National Jewish Medical And Research Center | Method for treatment of inflammatory disease |
PT1024814E (pt) | 1997-10-22 | 2007-11-29 | Mayo Foundation | Utilização de agentes antifúngicos para o tratamento tópico de mucosite induzida por fungo |
WO2001012646A1 (en) | 1999-08-19 | 2001-02-22 | Smithkline Beecham Corporation | Sialoadhesin factor-1 agonist and antagonist antibodies |
US20030017169A1 (en) | 2000-12-29 | 2003-01-23 | Sidney Pestka | Controlled release systems for polymers |
AU2003220525A1 (en) * | 2002-03-29 | 2003-10-20 | Abgenix, Inc. | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same |
US7339507B1 (en) * | 2006-09-13 | 2008-03-04 | Jiun-In Guo | Device for video decoding |
JP5364589B2 (ja) | 2006-12-11 | 2013-12-11 | ブラッコ・イメージング・ソシエタ・ペル・アチオニ | 診断および治療適用用フィブリン結合ペプチドコンジュゲート |
EP2152310A4 (en) * | 2007-04-30 | 2010-05-26 | Glaxosmithkline Llc | METHODS OF ADMINISTERING ANTI-IL-5 ANTIBODIES |
US20090035216A1 (en) | 2007-08-03 | 2009-02-05 | Biomonitor Aps | Method for determining in vivo biopharmaceutical concentration or bioavailability |
BRPI0910854A2 (pt) | 2008-03-28 | 2015-10-06 | Glaxosmithkline Llc | métodos de tratamento |
US8926631B2 (en) | 2010-08-06 | 2015-01-06 | MoMelan Technologies, Inc. | Methods for preparing a skin graft without culturing or use of biologics |
CN107837395A (zh) | 2011-02-09 | 2018-03-27 | 葛兰素史密斯克莱有限责任公司 | 冻干制剂 |
-
2009
- 2009-03-27 BR BRPI0910854A patent/BRPI0910854A2/pt not_active IP Right Cessation
- 2009-03-27 MX MX2010010667A patent/MX2010010667A/es not_active Application Discontinuation
- 2009-03-27 AU AU2009228163A patent/AU2009228163B2/en not_active Ceased
- 2009-03-27 KR KR1020107024046A patent/KR20100134702A/ko not_active Application Discontinuation
- 2009-03-27 CA CA2719786A patent/CA2719786A1/en not_active Abandoned
- 2009-03-27 EP EP09725345.4A patent/EP2274009B1/en not_active Revoked
- 2009-03-27 US US12/935,038 patent/US9834600B2/en active Active
- 2009-03-27 WO PCT/US2009/038509 patent/WO2009120927A2/en active Application Filing
- 2009-03-27 EA EA201071137A patent/EA201071137A1/ru unknown
- 2009-03-27 ES ES09725345.4T patent/ES2441945T3/es active Active
- 2009-03-27 CN CN2009801176573A patent/CN102026660A/zh active Pending
- 2009-03-27 JP JP2011502090A patent/JP5917143B2/ja active Active
-
2010
- 2010-09-16 ZA ZA2010/06648A patent/ZA201006648B/en unknown
- 2010-09-21 IL IL208354A patent/IL208354A0/en unknown
-
2014
- 2014-08-01 JP JP2014158170A patent/JP6069267B2/ja active Active
-
2016
- 2016-11-01 JP JP2016214438A patent/JP6457463B2/ja active Active
-
2017
- 2017-11-06 US US15/804,104 patent/US20180057582A1/en not_active Abandoned
-
2018
- 2018-12-20 JP JP2018238018A patent/JP2019065029A/ja active Pending
-
2019
- 2019-09-19 US US16/575,903 patent/US11325972B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014240408A5 (ja) | ||
JP2011516422A5 (ja) | ||
JP2018184417A5 (ja) | ||
JP2015529225A5 (ja) | ||
JP2015007098A5 (ja) | ||
JP2015525798A5 (ja) | ||
JP2018505882A5 (ja) | ||
JP2016515124A5 (ja) | ||
JP2013527233A5 (ja) | ||
RU2019134341A (ru) | (+)-альфа-дигидротетрабеназин для использования при лечении двигательного расстройства | |
JP2017534638A5 (ja) | ||
JP2012046518A5 (ja) | ||
JP2014530226A5 (ja) | ||
JP2016536361A5 (ja) | ||
JP2017160178A5 (ja) | ||
WO2007145941A8 (en) | Administration of anti-cd3 antibodies in the treatment of autoimmune diseases | |
MD20140059A2 (en) | Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases | |
JP2012193216A5 (ja) | ||
PH12018501903A1 (en) | Methods of treating depression using orexin-2 receptor antagonists | |
JP2015505564A5 (ja) | ||
RU2017134443A (ru) | Способ лечения с применением традипитанта | |
HRP20231015T1 (hr) | Upotreba antagonista il-13 u liječenju atopičnog dermatitisa | |
GR1007832B (el) | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" | |
CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
JP2018512402A5 (ja) |